Anteris Technologies Global (ASX: AVR) broadened recruitment in its global PARADIGM Trial during the second quarter of 2026, with the first US patients enrolled and treated in May. The PARADIGM Trial is evaluating the DurAVR transcatheter heart valve (THV) against commercially available transcatheter aortic valve replacement (TAVR) devices as Anteris works towards potential commercialisation of its lead product. “Q2 marked an important period of execution for Anteris as we advanced the PARADIGM Trial across clinical, regulatory and reimbursement milestones,” chief executive officer Wayne Paterson said. Research and development expenses reached US$23.4m as Anteris scaled manufacturing and quality capabilities, including process development and validation, increased headcount, and expanded trial activity. R&D spending also incorporated clinical costs associated with patient enrolment and expansion of the field-based clinical team, partly offset by lower DurAVR THV product research costs.